Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for PROCEPT BioRobotics (PRCT) over the last 6 years, with Q3 2025 value amounting to $14.5 million.

  • PROCEPT BioRobotics' Share-based Compensation rose 7021.03% to $14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.8 million, marking a year-over-year increase of 6529.42%. This contributed to the annual value of $31.8 million for FY2024, which is 6640.54% up from last year.
  • Per PROCEPT BioRobotics' latest filing, its Share-based Compensation stood at $14.5 million for Q3 2025, which was up 7021.03% from $12.2 million recorded in Q2 2025.
  • In the past 5 years, PROCEPT BioRobotics' Share-based Compensation registered a high of $14.5 million during Q3 2025, and its lowest value of $650000.0 during Q1 2021.
  • Its 5-year average for Share-based Compensation is $5.4 million, with a median of $5.0 million in 2023.
  • As far as peak fluctuations go, PROCEPT BioRobotics' Share-based Compensation skyrocketed by 26910.34% in 2022, and later skyrocketed by 5230.4% in 2025.
  • Quarter analysis of 5 years shows PROCEPT BioRobotics' Share-based Compensation stood at $1.5 million in 2021, then soared by 92.85% to $2.9 million in 2022, then surged by 72.65% to $5.0 million in 2023, then soared by 82.39% to $9.1 million in 2024, then soared by 59.49% to $14.5 million in 2025.
  • Its Share-based Compensation stands at $14.5 million for Q3 2025, versus $12.2 million for Q2 2025 and $10.1 million for Q1 2025.